The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 5, 2007, Pages 527-535

  Onay Besikci, Arzu ^a   Guner, Sahika ^a   Arioglu, Ebru ^a   Ozakca, Isil ^a   Ozcelikay, A Tanju ^a   Altan, V Melih ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

3 KAT; Cardiac fatty acid oxidation; Diabetes; Trimetazidine

Indexed keywords

GLUCOSE; INSULIN; STREPTOZOCIN; TRIMETAZIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; HEART MUSCLE CONTRACTILITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ACETYL-COA C-ACYLTRANSFERASE; ANIMALS; BODY MASS INDEX; CARDIAC OUTPUT; CORONARY CIRCULATION; DIABETES MELLITUS, EXPERIMENTAL; DRINKING; FATTY ACIDS; GLUCOSE; HEART; HEART RATE; MALE; MYOCARDIUM; OXIDATION-REDUCTION; PALMITIC ACID; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STREPTOZOCIN; TRIMETAZIDINE; TROMETHAMINE; VASODILATOR AGENTS;

EID: 34548155493     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y07-036     Document Type: Article

References (41)

1. Barger, P.M., and Kelly, D.P. 2000. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 10: 238-245. doi:10.1016/S1050-1738(00)00077-3.
2. Belardinelli, R., and Purcaro, A. 2001. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur. Heart J. 22: 2164-2170. doi:10.1053/euhj.2001.2653.
3. Carley, A.N., and Severson, D.L. 2005. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim. Biophys. Acta, 1734: 112-126.
4. D'Hahan, N., Taouil, K., Dassaouli, A., and Morel, J.E. 1997. Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6. Eur. J. Pharmacol. 328: 163-174. doi:10.1016/S0014-2999(97)83042-7.
5. Dalla-Volta, S., Maraglino, G., Della-Valentina, P., Viena, P., and Desideri, A. 1990. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc. Drugs Ther. 4: 853-859. doi:10.1007/BF00051292.
6. Detry, J.M., Sellier, P., Pennaforte, S., Cokkinos, D., Dargie, H., and Mathes, P. 1994. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br. J. Clin. Pharmacol. 37: 279-288.
7. Drake-Holland, A.J., Belcher, P.R., Hynd, J., and Noble, M.I.J. 1993. Infarct size in rabbits: a modified method illustrated by the effects of propranolol and trimetazidine. Basic Res. Cardiol. 88: 250-258.
8. Finck, B.N., Lehman, J.J., Leone, T.C., Welch, M.J., Bennett, M.J., Kovacs, A., et al. 2002. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109: 121-130. doi:10.1172/JCI200214080.
9. Fragasso, G., Piatti, P.M., Monti, L., Palloshi, A., Setola, E., Puccetti, P., et al. 2003. Short and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am. Heart J. 146: E18.
10. Hugtenburg, J.G., Jap, T.J., Mathy, M.J., van Heiningen, P.N., Bohnenn, V.A., Heijnis, J.B., Boddeke, H.W., and van Zwieten, P.A. 1989. Cardioprotective effect of trimetazidine and nifedipine in guinea-pig hearts subjected to ischaemia. Arch. Int. Pharmacodyn. Ther. 300: 186-208.
11. Inci, I., Dutly, A., Rousson, V., Boehler, A., and Weder, W. 2001. Trimetazidine protects the energy status after ischemia and reduces reperfusion injury in a rat single lung transplant model. J. Thorac. Cardiovasc. Surg. 122: 1155-1161. doi:10.1067/mtc.2001.114941.
12. Kantor, P.F., Lucien, A., Kozak, R., and Lopaschuk, G.D. 2000. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 86: 580-588.
13. Kara, A.F., Demiryurek, S., Celik, A., Tarakcioglu, M., and Demiryurek, A.T. 2004. Effects of trimetazidine on myocardial preconditioning in anesthetized rats. Eur. J. Pharmacol. 503: 135-145. doi:10.1016/j.ejphar. 2004.09.037.
14. Kober, G., Buck, T., Sievert, H., and Vallbracht, C. 1992. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur. Heart J. 13: 1109-1115.
15. Levy, S. 1995. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Group of the south of France investigators. Am. J. Cardiol. 76: 12B-16B. doi:10.1016/0002-9149(95) 90058-6.
16. Libersa, C., Honore, E., Adamantidis, M., Rouet, E., and Dupuis, B. 1990. Antiischaemic effect of trimetazidine: enzymatic and electric response in a model of in vitro myocardial ischaemia. Cardiovasc. Drugs Ther. 4: 808-809. doi:10.1007/BF00051279.
17. Liu, B., Clanachan, A.S., Schulz, R., and Lopaschuk, G.D. 1996. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ. Res. 79: 940-948.
18. Lopaschuk, G.D. 1996. Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrate/Lipid metabolism. Coron. Artery Dis. 7: 116-123.
19. Lopaschuk, G.D., and Spafford, M. 1989. Response of isolated working hearts to fatty acids and carnitine palmitoyltransferase I inhibition during reduction of coronary flow in acutely and chronically diabetic rats. Circ. Res. 65: 378-387.
20. Lopaschuk, G.D., Barr, R., Thomas, P.D., and Dyck, J.R. 2003. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ. Res. 93: e33-e37. doi:10.1161/01.RES.0000086964.07404.A5.
21. Manchanda, S.C., and Krishnaswami, S. 1997. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart, 78: 353-357.
22. 2+ handling in isoprenaline-mediated myocardial injury of rats. Exp. Physiol. 91: 591-601. doi:10.1113/expphysiol.2005.032615.
23. Mody, F.V., Singh, B.N., Mohiuddin, I.H., Coyle, K.B., Buxton, D.B., Hansen, H.W., Sumida, R., and Schelbert, H.R. 1998. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischaemic myocardial tissue: an evaluation by positron emission tomography. Am. J. Cardiol. 82: 42K-49K. doi:10.1016/S0002-9149(98)00536-0.
24. Monpere, C., Brochier, M., Demange, J., Ducloux, G., and Warin, J.F. 1990. Combination of trimetazidine with nifedipine in effort angina. Cardiovasc. Drugs Ther. 4: 824-825. doi:10.1007/BF00051287.
25. Monti, L.D., Allibardi, S., Piatti, P.M., Valsecchi, G., Costa, S., Pozza, G., Chierchia, S., and Samaja, M. 2001. Triglycerides impair postischemic recovery in isolated hearts: roles of endothelin-1 and trimetazidine. Am. J. Physiol. Heart Circ. Physiol. 281: H1122-H1130.
26. Onay-Besikci, A. 2007. Impact of lactate in the perfusate on function and metabolic parameters of isolated working rat heart. Mol. Cell. Biochem. 296: 121-127. doi:10.1007/s11010-006-9305-5.
27. Rosano, G.M., Vitale, C., Sposato, B., Mercuro, G., and Fini, M. 2003. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc. Diabetol. 2: 16. doi:10.1186/1475-2840-2-16.
28. Sellier, P. 1986. The effects of trimetazidine on ergometric parameters in exercise-induced angina. Controlled multicenter double blind versus placebo study. Arch. Mal. Coeur Vaiss. 79: 1331-1336.
29. Sellier, P., Audouin, P., Payen, B., Corona, P., Duong, T.C., and Ourbak, P. 1987. Acute effects of trimetazidine evaluated by exercise testing. Eur. J. Clin. Pharmacol. 33: 205-207. doi:10.1007/BF00544569.
30. Sentex, E., Sergiel, J.P., Lucien, A., and Grynberg, A. 1997. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol. Cell. Biochem. 175: 153-162. doi:10.1023/A:1006813403448.
31. Sentex, E., Sergiel, J.P., Lucien, A., and Grynberg, A. 1998. Is the cytoprotective effect of trimetazidine associated with lipid metabolism. Am. J. Cardiol. 82: 18K-24K. doi:10.1016/S0002-9149(98)00533-5.
32. Sentex, E., Helies-Toussaint, C, Rousseau, D., Lucien, A., Ferrary, E., and Grynberg, A. 2001. Influence of trimetazidine on the synthesis of complex lipids in the heart and other target organs. Fundam. Clin. Pharmacol. 15: 255-264. doi:10.1046/j.1472-8206.2001.00031.x.
33. Stanley, W.C., Lopaschuk, G.D., and McCormack, J.G. 1997. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc. Res. 34: 25-33. doi:10.1016/S0008-6363(97)00047-3.
34. Szwed, H., Sadowski, Z., Pachocki, R., Domzal-Bochenska, M., Szymczak, K., Szydlowski, Z., et al. 1999. The antiischaemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc. Drugs Ther. 13: 217-222. doi:10.1023/A:1007744109064.
35. Szwed, H., Hradec, J., and Preda, I. 2001a. Anti-ischaemicc efficacy and tolerability of trimetazidine administered to patients with angina pectoris: results of three studies. Coron. Artery Dis. 12: S25-S28.
36. Szwed, H., Sadowski, Z., Pachocki, R., Domzal-Bochenska, M., Szymczak, K., Szydlowski, Z., et al. 2001b. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur. Heart J. 22: 2267-2274. doi:10.1053/euhj.2001.2896.
37. Tabbi-Anneni, I., Helies-Toussaint, C., Morin, D., Bescond-Jacquet, A., Lucien, A., and Grynberg, A. 2003. Prevention of heart failure in rats by trimetazidine treatment: a consequence of accelerated phospholipid turnover? J. Pharmacol. Exp. Ther. 304: 1003-1009.
38. Taegtmeyer, H., McNulty, P., and Young, M.E. 2002. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation, 105: 1727-1733. doi:10.1161/01.CIR.0000012466.50373.E8.
39. Topal, E., Ozdemir, R., Barutcu, I., Aksoy, Y., Sincer, I., Akturk, E., and Cehreli, S. 2006. The effects of trimetazidine on heart rate variability in patients with slow coronary artery flow. J. Electrocardiol. 39: 211-218. doi:10.1016/j.jelectrocard.2005.08.011.
40. Yechoor, V.K., Patti, M.E., Saccone, R., and Kahn, C.R. 2002. Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 99: 10587-10592. doi:10.1073/pnas.142301999.
41. Young, M.E., McNulty, P., and Taegtmeyer, H. 2002. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation, 105: 1861-1870. doi:10.1161/01.CIR.0000012467.61045.87.